Adverse events of colonoscopy in a colorectal cancer screening program with fecal immunochemical testing: a population-based observational study

Abstract

Background and study aims The aim of this study was to assess adverse events (AEs) associated with colonoscopy in the French colorectal cancer screening program with fecal occult blood test (FOBT).

Patients and methods A retrospective cohort study was performed of all colonoscopies performed from 2015 to 2018 for a positive fecal immunochemical test (FIT) in patients aged 50 to 74 years within the screening program in progress in Alsace, part of the French program. AEs were recorded through prospective voluntary reporting by community gastroenterologists and retrospective postal surveys addressed to individuals screened. They were compared with those recorded in the previous program following colonoscopies performed from 2003 to 2014 for a positive guaiac-based FOBT (gFOBT).

Results Of 9576 colonoscopies performed for a positive FIT, 6194 (64.7 %) were therapeutic. Overall, 180 AEs were recorded (18.8 ‰, 95 % CI 16.1–21.5), 114 of them (11.9 ‰, 95 % CI 9.7–14.1) requiring hospitalization, 55 (5.7‰, 95 % CI 4.2–7.3) hospitalization > 24 hours, and eight (0.8 ‰, 95 % CI 0.3–1.4) surgery. The main complications requiring hospitalization were perforation (n = 18, 1.9 ‰, 95 % CI 1.0–2.7) and bleeding (n = 31, 3.2 ‰, 95 % CI 2.1–4.4). Despite a significant increase in several risk factors for complication, the rate of AEs remained stable between gFOBT and FIT programs. Overall, we observed one death (1/27,000 colonoscopies) and three splenic injuries.

Conclusions The harms of colonoscopy in a colorectal cancer screening program with FIT are more frequent than usually estimated. This study revealed six AEs requiring hospitalization > 24 hours (three bleeds, two perforations), one necessitating surgery, and 50 minor complications per 1000 colonoscopies.

Publikationsverlauf

Eingereicht: 27. Juni 2020

Angenommen: 22. Oktober 2020

Artikel online veröffentlicht:
03. Februar 2021

• References

• 1 GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 4: 913-933
• 2 Holme Ø, Bretthauer M, Fretheim A. et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013; 9: CD009259 Review
• 3 Senore C, Basu P, Anttila A. et al. Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut 2019; 68: 1232-1244
• 4 Bretthauer M, Kalager M, Adami HO. Do's and don'ts in evaluation of endoscopic screening for gastrointestinal cancers. Endoscopy 2016; 48: 75-80
• 5 Heleno B, Thomsen MF, Rodrigues DS. et al. Quantification of harms in cancer screening trials: literature review. BMJ 2013; 347: f5334 Review
• 6 Denis B, Gendre I, Sauleau EA. et al. Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study. Dig Liver Dis 2013; 45: 474-480
• 7 Arana-Arri E, Imaz-Ayo N, Fernández MJ. et al. Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a population-based program: A nested case-control study. United European Gastroenterol J 2018; 6: 755-764
• 8 Mikkelsen EM, Thomsen MK, Tybjerg J. et al. Colonoscopy-related complications in a nationwide immunochemical fecal occult blood test-based colorectal cancer screening program. Clin Epidemiol 2018; 10: 1649-1655
• 9 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
• 10 Rutter MD, Nickerson C, Rees CJ. et al. Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme. Endoscopy 2014; 46: 90-97
• 11 Robertson DJ, Lee JK, Boland CR. et al. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 152: 1217-1237
• 12 Denis B, Ruetsch M, Strentz P. et al. Short-term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 2007; 56: 1579-1584
• 13 Denis B, Gendre I, Perrin P. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study. J Med Screen 2015; 22: 76-82
• 14 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 15 Portillo I, Idigoras I, Bilbao I. et al. Colorectal cancer screening program using FIT: quality of colonoscopy varies according to hospital type. Endosc Int Open 2018; 6: E1149-E1156
• 16 Lee TJ, Rutter MD, Blanks RG. et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012; 61: 1050-1057
• 17 Quyn AJ, Fraser CG, Stanners G. et al. Scottish Bowel Screening Programme colonoscopy quality - scope for improvement?. Colorectal Dis 2018; 20: 277-283
• 18 Ferlitsch M, Reinhart K, Pramhas S. et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306: 1352-1358
• 19 Reumkens A, Rondagh EJ, Bakker CM. et al. Post-colonoscopy complications: a systematic review, time trends, and meta-analysis of population-based studies. Am J Gastroenterol 2016; 111: 1092-1101
• 20 Lin JS, Piper M, Perdue LA. et al. Screening for Colorectal Cancer: An Updated Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05203-EF-1
• 21 Pox CP, Altenhofen L, Brenner H. et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-1467
• 22 Lee TJ, Rees CJ, Nickerson C. et al. Management of complex colonic polyps in the English Bowel Cancer Screening Programme. Br J Surg 2013; 100: 1633-1639
• 23 Ko CW, Riffle S, Michaels L. et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol 2010; 8: 166-173
• 24 Adler A, Lieberman D, Aminalai A. et al. Data quality of the German screening colonoscopy registry. Endoscopy 2013; 45: 813-818
• 25 Rutter MD, Beintaris I, Valori R. et al. World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. Gastroenterology 2018; 155: 909-925
• 26 Hassan C, Repici A, Sharma P. et al. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. Gut 2016; 65: 806-820
• 27 de Neree Tot Babberich MPM, Bronzwaer MES, Andriessen JO. et al. Outcomes of surgical resections for benign colon polyps: a systematic review. Endoscopy 2019; 51: 961-972
• 28 Peery AF, Cools KS, Strassle PD. et al. Increasing rates of surgery for patients with nonmalignant colorectal polyps in the United States. Gastroenterology 2018; 154: 1352-1360
• 29 Le Roy F, Manfredi S, Hamonic S. et al. Frequency of and risk factors for the surgical resection of non-malignant colorectal polyps: a population-based study. Endoscopy 2016; 48: 263-270